Emergent BioSolutions to Webcast Presentations at Upcoming Investor Conferences
Business Wire
Nov 02, 2009
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company
will be webcasting its presentation at the following investor
conferences during the month of November 2009.
-
The Southwest Ideas Conference
Dallas, TX.
November 11, 2009
Presentation
Time: 11:30 AM Central
-
The 6th Annual Lazard Capital Markets Healthcare Conference
New
York, NY.
November 17, 2009
Presentation Time: 8:55 AM
Eastern
During each presentation, a member of the company’s senior management
team will provide a corporate overview, including a discussion of
product development programs, corporate activities and financial
performance.
A webcast of these presentations will be available both live and by
replay, accessible from the company’s website www.emergentbiosolutions.com
under “Investors”.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the
development, manufacture and commercialization of vaccines and
therapeutics that assist the body’s immune system to prevent or treat
disease. Emergent’s marketed product, BioThrax® (Anthrax
Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and
Drug Administration for the prevention of anthrax disease. Emergent’s
development pipeline includes programs focused on anthrax, botulism,
tuberculosis, typhoid, hepatitis B and chlamydia. Additional information
may be found at www.emergentbiosolutions.com.
(c) 2009 Business Wire, Inc., All rights reserved. All of the news releases and other content contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. Any copying or reproduction (other than for an individual user's personal reference), redistribution, reposting or other transmission or communication is expressly prohibited without prior written permission of Business Wire, Inc
